menu
    • menu

    Company profile for Sarepta Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our vision is to transform how the world approaches the treatment of serious and life-threatening diseases by unlocking the potential of RNA-based technologies. Recognizing the complexity of this goal, we focus on rare neuromuscular diseases which represent tremendous unmet needs—areas in which new therapies have the potential to make dramatic improvements in the lives of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sarepta TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    215 First Street Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sarepta.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sarepta-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/sarepta

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sarepta to Test Elevidys with Immunosuppressive Regimen
    Sarepta to Test Elevidys with Immunosuppressive Regimen

    26 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125916203/en/Sarepta-Announces-Approval-to-Begin-ENDEAVOR-Cohort-8-to-Evaluate-Enhanced-Immunosuppression-Regimen-as-Part-of-ELEVIDYS-Gene-Therapy-for-Non-Ambulant-Individuals-with-Duchenne

    BUSINESSWIRE
    26 Nov 2025
    Share Share
    Arrowhead Pharma Receives $200M Milestone Payment From Sarepta
    Arrowhead Pharma Receives $200M Milestone Payment From Sarepta

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124338777/en/Arrowhead-Pharmaceuticals-Earns-%24200-Million-Milestone-Payment-from-Sarepta-Therapeutics

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Sarepta Updates SRP-1003 for Type 1 Myotonic Dystrophy
    Sarepta Updates SRP-1003 for Type 1 Myotonic Dystrophy

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124527957/en/Sarepta-Provides-Progress-Update-for-SRP-1003-its-Investigational-siRNA-treatment-for-Myotonic-Dystrophy-Type-1

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    FDA Narrows Elevidys Duchenne Gene Therapy Patient Pool
    FDA Narrows Elevidys Duchenne Gene Therapy Patient Pool

    14 Nov 2025

    // FDA

    https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal?utm_medium=email&utm_source=govdelivery

    FDA
    14 Nov 2025
    Share Share
    Sarepta, Despite Key Trial Flop, Will Seek Full Nod For DMD Meds
    Sarepta, Despite Key Trial Flop, Will Seek Full Nod For DMD Meds

    04 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/sarepta-pushes-full-approval-duchenne-drugs-despite-missed-confirmatory-trial-goal

    FIERCE PHARMA
    04 Nov 2025
    Share Share
    Sarepta Reveals Q3 2025 Financials, Confirms ESSENCE Study
    Sarepta Reveals Q3 2025 Financials, Confirms ESSENCE Study

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103268367/en/Sarepta-Therapeutics-Announces-Third-Quarter-2025-Financial-Results-and-Recent-Corporate-Developments-Including-Completion-of-Its-Confirmatory-Study-ESSENCE

    BUSINESSWIRE
    03 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Contact Sarepta Therapeutics and get a quotation

    Sarepta Therapeutics is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find a price of AVI 4126 bulk offered by Sarepta Therapeutics

    Find a price of SRP-2001 DRUG SUBSTANCE bulk offered by Sarepta Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search